We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00410930
First Posted: December 13, 2006
Last Update Posted: December 19, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Stallergenes Greer
  Purpose
To compare versus placebo the efficacy and safety of recombinant Bet v1, natural purified Bet v1 and birch pollen licenced extract used for subcutaneous immunotherapy.

Condition Intervention Phase
Allergy Biological: Subcutaneous immunotherapy - Recombinant birch pollen Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Double-Blind Placebo-Controlled Study of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients

Further study details as provided by Stallergenes Greer:

Primary Outcome Measures:
  • Reduction of symptom and medication scores.

Estimated Enrollment: 160
Study Start Date: November 2002
Estimated Study Completion Date: November 2005
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients aged 18-50 with seasonal rhinoconjunctivitis for at least 2 years, and/or mild asthma range 1 and 2 GINA.
  • Positive history of birch pollen allergy (clinical history, positive skin prick test, birch specific IgE, presence of birch pollen)
  • Compliant patients
  • Written consent.

Exclusion Criteria:

  • Perennial rhinoconjunctivitis and/or asthma due to cosensitization with: animal danders, mites, alternaria cladosporium
  • Uncontrolled seasonal asthma : severe asthma permanent or not range 3 and 4 of GINA.
  • Patients treated with beta-blockers or under continuous oral corticosteroids.
  • Pregnant women
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00410930


Locations
France
Pr Gabrielle PAULI
Strasbourg, France, 67091
Sponsors and Collaborators
Stallergenes Greer
Investigators
Principal Investigator: Gabrielle PAULI, MD, Pr Hôpital Liautey - Strasbourg, France
  More Information

ClinicalTrials.gov Identifier: NCT00410930     History of Changes
Other Study ID Numbers: DV08.01
First Submitted: December 12, 2006
First Posted: December 13, 2006
Last Update Posted: December 19, 2006
Last Verified: December 2006

Keywords provided by Stallergenes Greer:
Immunotherapy, major allergen, birch